A. Barbaud

Summary This study from France concerned itself with the biologic drug, omalizumab, as treatment for chronic spontaneous urticaria (CSU). CSU causes troublesome, even debilitating, itchy weals like nettle stings (urticaria), together with swelling of deeper tissues (angioedema) that commonly affects the lips, tongue and eyelids. Omalizumab is licensed for severe CSU that does not respond to high‐dose antihistamines.

Summary 这项来自法国的研究本身关注生物药奥玛朱单抗作为慢性自发性荨麻疹 (CSU) 的治疗。CSU 导致棘手(甚至致人衰弱)的瘙痒性鞭痕样荨麻刺伤(荨麻疹)以及通常影响口唇、舌和眼睑等较深部组织的肿胀(血管性水肿)。奥马珠单抗被批准用于对高剂量抗组胺药无效的重度 CSU。入组了 136名 CSU 患者,124 名完成了研究。向他们给予 3 剂标准剂量奥马珠单抗,每 4 周一次,共 12 周。半数患者还使用了其他药物(通常为抗组胺药物)来治疗他们的 CSU。研究者和参与者们知道所有参与者正在使用奥马珠单抗,且没有安慰剂组。发现两种评估改善的评分方法 (现有的 7 ‐天荨麻疹活动评分 UAS7 和较新的荨麻疹控制试验 UCT)存在相关性,即它们的评分相似。根据 UAS7 评分测量结果,奥马珠单抗在 2/3 患者中有效,根据 UCT 评分,在 3/4 患者中有效。这些结果不受患者有无血管性水肿影响。生活质量评分显著改善。血液中名为 D‐二聚体的蛋白的平均水平在研究开始时增高,通过治疗下降,但与 UAS7 或 UCT 评分改善无关联。8/9 患者治疗后的...

Erosive lichen planus (ELP) is a chronic inflammatory disease characterized by erosive and painful lesions affecting oral and genital mucosa, and more rarely conjunctival, auricular and esophageal mucosa and skin1. ELP may be associated with considerable morbidity and quality of life impairment and can lead to severe complications such as vaginal and esophageal stenosis or squamous cell carcinoma1.